Treatment Outcomes of Retroperitoneal Sarcoma

Prognostic Factors and Oncological Outcome Analysis of Retroperitoneal Sarcoma

Investigators tried condult a retrospective study to analysis the prognostic factors and oncological outcome analysis of Retroperitoneal Sarcoma treated in our high volume medical center.

Study Overview

• Status: Active, not recruiting
• Conditions: Retroperitoneal Sarcoma
• Intervention / Treatment: Procedure: tumor wide excision

Detailed Description

Retroperitoneal Sarcoma (RPS) which is a rare disease which incidence is 1.79/100,000. The treatment is difficult to due to it anatomy position which often invade to multiple organs and cause the complete surgical resection to be very complex and difficult. It was known to sacrifice one side kidney will improve the resection rate. To this days, successful surgical resection was still the gold standard that provide most benefit in overall survival. To reach that goal, pre-operative radiotherapy was applied to RPS which intended to achieve similar effect in rectal cancer for the down staging effect and improved the respectability but with limited benefit. Herein, investigators conducted this study to find the best way to achieve successful surgical resection and prognostic factor analysis.

• Study Type: Observational
• Enrollment (Estimated): 150

Contacts and Locations

Study Locations

• Taiwan
  • Taichung, Taiwan
    • Taichung Veterans General Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

• Sampling Method: Probability Sample

Study Population

the patient who have retroperitoneal maliganacy and receive complete tumor excision in our hospital. The preoperative procedure including angiography or TAE, radiotherapy is allowed.

Description

Inclusion Criteria:

• the patient who have retroperitoneal maliganacy and receive complete tumor excision in our hospital

Exclusion Criteria:

• the patient did not receive complete tumor excision in our hospital
• the pathological report yielded not malignancy tumor

Study Plan

How is the study designed?

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Overall survival	After treatment, patients will undergo long-term follow-up to record their survival status.	The proportion of patients still alive at 1 year, 3 years, and 5 years after treatment.

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Progression free survival	Progression defined as local, regional, or distant metastasis	The rates of local recurrence, regional recurrence, or distant metastasis at 1 year, 3 years, and 5 years after treatment.

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
The resectability of preoperative embolization	Preoperative embolization for assessing resectability combines radiology, angiography, and transcatheter arterial embolization (TAE). Initially, imaging techniques such as X-rays or CT scans are used to understand the characteristics of the lesions. Then, angiography is employed to observe the tumor's blood supply. Finally, TAE not only evaluates the vascular supply to the tumor but also helps reduce its size through embolization, enhancing resectability. The comprehensive results of these assessments contribute to developing a safe and effective surgical plan.	From the start of preoperative evaluations to the day of surgery, it typically spans 7 days.
The value of eGFR in renal function	eGFR is an important biomarker used to assess kidney function and monitor renal health. It represents the volume of blood filtered by the glomeruli per minute, typically expressed in milliliters per minute (mL/min). A venous blood sample will be collected and analyzed in the laboratory to determine the value.	Period from date before surgery to the date one year after suregry

Collaborators and Investigators

• Sponsor: Taichung Veterans General Hospital
• Investigators: Principal Investigator: Radiation-Oncology Department Liu, M.D., Department of Radiation-Oncology, Taichung Veterans General Hospital

Study record dates

Study Major Dates

• Study Start (Actual): October 1, 2023
• Primary Completion (Actual): July 1, 2024
• Study Completion (Estimated): September 30, 2025

Study Registration Dates

• First Submitted: September 9, 2023
• First Submitted That Met QC Criteria: September 22, 2024
• First Posted (Actual): September 25, 2024

Study Record Updates

• Last Update Posted (Actual): September 25, 2024
• Last Update Submitted That Met QC Criteria: September 22, 2024
• Last Verified: September 1, 2024

More Information

Terms related to this study

• Keywords: Surgery; Radiotherapy; Retroperitoneal Sarcoma
• Additional Relevant MeSH Terms: Neoplasms, Connective and Soft Tissue; Neoplasms by Histologic Type; Neoplasms; Sarcoma
• Other Study ID Numbers: CE23365A

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED
• IPD Plan Description: I would like to share after the paper publish.

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No